{"id":"dpp4-inhibitor","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Nasopharyngitis"},{"rate":"5-8","effect":"Headache"},{"rate":"4-7","effect":"Upper respiratory tract infection"},{"rate":"variable","effect":"Hypoglycemia (when combined with other agents)"},{"rate":null,"effect":"Pancreatitis"}]},"_chembl":{"chemblId":"CHEMBL5715921","moleculeType":null,"molecularWeight":"652.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DPP4 inhibitors work by inhibiting the degradation of GLP-1 and GIP, incretin hormones released after meals that enhance glucose-dependent insulin secretion and suppress glucagon. By preventing the breakdown of these hormones, DPP4 inhibitors increase their circulating levels and duration of action, leading to improved glycemic control in type 2 diabetes. This mechanism is glucose-dependent, meaning insulin is only stimulated when blood glucose is elevated, reducing hypoglycemia risk.","oneSentence":"DPP4 inhibitors block the enzyme dipeptidyl peptidase-4, which prolongs the activity of incretin hormones that stimulate insulin secretion in response to glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:51.510Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07460336","phase":"NA","title":"Effects of Cofrogliptin on Beta-Cell Function in LADA Patients","status":"NOT_YET_RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-03-15","conditions":"Latent Autoimmune Diabetes in Adults (LADA)","enrollment":84},{"nctId":"NCT03499704","phase":"PHASE4","title":"A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2020-02-11","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT07465926","phase":"","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2017-01-01","conditions":"Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease","enrollment":451036},{"nctId":"NCT06495281","phase":"","title":"Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-10-26","conditions":"Type 2 Diabetes Mellitus","enrollment":2044},{"nctId":"NCT07439536","phase":"PHASE4","title":"Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2024-07-01","conditions":"Liver Cirrhosis With Diabetes","enrollment":64},{"nctId":"NCT07436663","phase":"PHASE4","title":"Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT03363464","phase":"","title":"Comparative Effectiveness of Empagliflozin in the US","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2017-10-16","conditions":"Diabetes Mellitus, Type 2","enrollment":230000},{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":"Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications","enrollment":7850},{"nctId":"NCT07374328","phase":"PHASE1, PHASE2","title":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-06-01","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT06263673","phase":"PHASE4","title":"Anti-Diabetic Medications to Fight PD and LBD","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-05-07","conditions":"Lewy Body Dementia, Parkinson Disease","enrollment":18},{"nctId":"NCT07365592","phase":"PHASE1, PHASE2","title":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"Colorectal Cancer","enrollment":138},{"nctId":"NCT07332156","phase":"","title":"Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-01-01","conditions":"Type 2 Diabetes, COPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis)","enrollment":21692},{"nctId":"NCT05313529","phase":"NA","title":"LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-10-08","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":396},{"nctId":"NCT02314637","phase":"PHASE3","title":"Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT07314684","phase":"PHASE4","title":"GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM","status":"RECRUITING","sponsor":"Federico II University","startDate":"2025-09-08","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":80},{"nctId":"NCT06528405","phase":"PHASE2","title":"The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-11-21","conditions":"Acute Kidney Injury","enrollment":264},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT07241897","phase":"PHASE3","title":"DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-12-15","conditions":"Ischemic Stroke, Diabete Mellitus","enrollment":312},{"nctId":"NCT05768945","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-30","conditions":"Diabetes","enrollment":742670},{"nctId":"NCT05214573","phase":"","title":"Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-12-01","conditions":"Type 2 Diabetes, Cardiac Disease","enrollment":386301},{"nctId":"NCT05755360","phase":"","title":"DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-02-21","conditions":"Diabetes Mellitus, Type 2","enrollment":291},{"nctId":"NCT07198191","phase":"","title":"SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2014-09-01","conditions":"Acute Myocardial Infarction (AMI), Type 2 Diabetes Mellitus (T2DM)","enrollment":200000},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT07108985","phase":"PHASE4","title":"Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-09","conditions":"Diabetes Mellitus, Type 2, Hyperglycemia, Insulin Resistance","enrollment":100},{"nctId":"NCT07073768","phase":"PHASE3","title":"Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Khyber Medical College, Peshawar","startDate":"2025-07-01","conditions":"Diabetes Mellitus Type 2, Glycemic Control for Diabetes Mellitus","enrollment":126},{"nctId":"NCT04735042","phase":"","title":"SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2020-10-07","conditions":"Type 2 Diabetes, Urinary Tract Infections","enrollment":60},{"nctId":"NCT04410341","phase":"PHASE1, PHASE2","title":"The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-05-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT01242228","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":106},{"nctId":"NCT03464045","phase":"","title":"Empa PASS on Urinary Tract Malignancies","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-11-16","conditions":"Diabetes Mellitus, Type 2","enrollment":344995},{"nctId":"NCT06875193","phase":"PHASE4","title":"DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2024-05-28","conditions":"Type2diabetes","enrollment":196},{"nctId":"NCT06838286","phase":"","title":"Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes","status":"RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2024-03-16","conditions":"Diabetes Mellitus, Type 2","enrollment":10000},{"nctId":"NCT02737657","phase":"","title":"An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2016-04","conditions":"Diabetes Mellitus, Type 2","enrollment":379},{"nctId":"NCT03793023","phase":"","title":"Observational Study to Evaluate the Efficacy and Safety of Teneligliptin","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2016-01-05","conditions":"Type 2 Diabetes Mellitus","enrollment":2983},{"nctId":"NCT06770894","phase":"PHASE3","title":"DPP4-Inhibitors and Bone Metabolism in Diabetes","status":"COMPLETED","sponsor":"Azienda Policlinico Umberto I","startDate":"2019-09-24","conditions":"Osteoporosis, Bone Loss, Postmenopausal, Diabetes Mellitus Type 2","enrollment":132},{"nctId":"NCT04727580","phase":"PHASE2","title":"HSK7653 in Chinese Patients with Impaired Glucose Tolerance","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2021-03-29","conditions":"Impaired Glucose Tolerance","enrollment":99},{"nctId":"NCT06703268","phase":"PHASE2","title":"A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2024-01-15","conditions":"Type 2 Diabetes","enrollment":64},{"nctId":"NCT03717194","phase":"PHASE3","title":"Effect of Ertugliflozin on Cardiac Function in Diabetes","status":"COMPLETED","sponsor":"Soo Lim","startDate":"2019-06-01","conditions":"Type2 Diabetes, Heart Failure","enrollment":102},{"nctId":"NCT02864914","phase":"","title":"Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-03-15","conditions":"Diabetes Mellitus, Type 2","enrollment":333580},{"nctId":"NCT06611904","phase":"NA","title":"The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Attikon Hospital","startDate":"2018-02-01","conditions":"Urine Albumin (UAlb), Glycocalyx, Arterial Stiffness","enrollment":60},{"nctId":"NCT03817463","phase":"","title":"A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-04-15","conditions":"Diabetes Mellitus, Type 2","enrollment":327624},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT03939624","phase":"","title":"Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Type2 Diabetes, Myocardial Infarction, Ischemic Stroke","enrollment":419734},{"nctId":"NCT06099067","phase":"","title":"Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-05-15","conditions":"Type 2 Diabetes Mellitus","enrollment":239990},{"nctId":"NCT04295005","phase":"","title":"A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-11-16","conditions":"Diabetes Mellitus, Type 2","enrollment":24500},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT02285985","phase":"PHASE4","title":"Effects of Saxagliptin on Adipose Tissue Inflammation in Humans","status":"COMPLETED","sponsor":"Phoenix VA Health Care System","startDate":"2013-02","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":103},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT05284344","phase":"","title":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2021-01-24","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT06145360","phase":"PHASE4","title":"Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient","status":"COMPLETED","sponsor":"SINA Health Education and Welfare Trust","startDate":"2023-12-01","conditions":"Glucose Metabolism Disorders, Diabetes Mellitus, Type 2, Hypoglycemic Agents","enrollment":150},{"nctId":"NCT06348706","phase":"PHASE3","title":"Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-11-10","conditions":"Diabetes Mellitus, Type 1, NASH","enrollment":60},{"nctId":"NCT05818995","phase":"","title":"Therapeutic Drug Use for CKD Patients","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2022-07-01","conditions":"Chronic Kidney Disease","enrollment":10000},{"nctId":"NCT06301191","phase":"","title":"The Effect of Semaglutide on Cardiovascular Markers and Liver Function","status":"RECRUITING","sponsor":"Attikon Hospital","startDate":"2022-03-01","conditions":"Diabetes Type 2","enrollment":50},{"nctId":"NCT06218342","phase":"PHASE4","title":"Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-02-15","conditions":"Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease","enrollment":156},{"nctId":"NCT03231709","phase":"PHASE4","title":"Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-08-18","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT03014479","phase":"PHASE4","title":"Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-18","conditions":"Type 2 Diabetes","enrollment":219},{"nctId":"NCT06164535","phase":"PHASE4","title":"The Effects of DPPIs on Cognitive Function of Diabetic Patients","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2023-12-30","conditions":"Cognitive Impairment","enrollment":105},{"nctId":"NCT03807440","phase":"","title":"DIA_CENTRAL:T2D Treatment Pattern in Central Europe","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-08-26","conditions":"Diabetes Mellitus, Type 2","enrollment":4083},{"nctId":"NCT06148259","phase":"NA","title":"SGLT Inhibitors Versus DDP4 Inhibitors and Prostate in Patient With Diabetes","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2021-03-12","conditions":"Diabetes Mellitus, Prostatic Hyperplasia","enrollment":57},{"nctId":"NCT05977465","phase":"PHASE1, PHASE2","title":"Empagliflozin in Treatment of Peripheral Diabetic Neuropathy","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-01-20","conditions":"Diabetic Neuropathy Peripheral","enrollment":50},{"nctId":"NCT03921242","phase":"","title":"Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2019-08-01","conditions":"Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic","enrollment":4888},{"nctId":"NCT06021119","phase":"PHASE3","title":"Feasibility of DPP-4 Inhibitor Therapy on Advanced Hybrid Closed Loop System","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-03-23","conditions":"Time in Range","enrollment":50},{"nctId":"NCT06010992","phase":"PHASE2","title":"Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-10-01","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT03877406","phase":"PHASE4","title":"Effect of Empagliflozin on Body Composition and Ketones","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-08-01","conditions":"Diabetes Mellitus, Fat; Intolerance, Pancreas","enrollment":200},{"nctId":"NCT03936049","phase":"","title":"Replication of the LEADER Diabetes Trial in Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-09-22","conditions":"Diabetes","enrollment":168690},{"nctId":"NCT04215523","phase":"","title":"Replication of the DECLARE Diabetes Trial in Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-07-08","conditions":"Diabetes","enrollment":49790},{"nctId":"NCT04215536","phase":"","title":"Replication of the EMPAREG Diabetes Trial in Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-07-08","conditions":"Diabetes","enrollment":103752},{"nctId":"NCT03936010","phase":"","title":"Replication of the CANVAS Diabetes Trial in Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-09-22","conditions":"Diabetes","enrollment":152202},{"nctId":"NCT05870462","phase":"PHASE4","title":"Semaglutide and Vascular Regeneration","status":"UNKNOWN","sponsor":"Canadian Medical and Surgical Knowledge Translation Research Group","startDate":"2023-04-29","conditions":"Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT05817097","phase":"","title":"Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database","status":"UNKNOWN","sponsor":"Ajou University School of Medicine","startDate":"2023-08","conditions":"Cerebral Infarction, Infarction, Brain, Dipeptidyl-Peptidase IV Inhibitors","enrollment":22119},{"nctId":"NCT05902468","phase":"PHASE2, PHASE3","title":"Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-06-28","conditions":"Diabetes Mellitus, Type 2","enrollment":88},{"nctId":"NCT02029846","phase":"PHASE4","title":"Glycemia in Diabetic Elders Trial","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2013-04","conditions":"Type 2 Diabetes Mellitus","enrollment":2},{"nctId":"NCT04419337","phase":"PHASE2","title":"Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Stroke","enrollment":200},{"nctId":"NCT03871621","phase":"PHASE4","title":"Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2019-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT05663736","phase":"PHASE4","title":"Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2020-01-01","conditions":"Ejection Fraction","enrollment":80},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT04825795","phase":"","title":"DPP4 Inhibitor and Coronary Atherosclerosis in Patients Receiving Insulin Therapy","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2010-01-01","conditions":"Diabetes Mellitus","enrollment":4007},{"nctId":"NCT05578352","phase":"NA","title":"The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-08-05","conditions":"Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT04161430","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-01-02","conditions":"Type 2 Diabetes Mellitus","enrollment":766},{"nctId":"NCT05347459","phase":"","title":"Cognitive Protective Effect of Newer Antidiabetic Drugs","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-03-02","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT05103306","phase":"","title":"Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT03748810","phase":"","title":"Head-to-head Comparison of Empagliflozin and Dapagliflozin","status":"COMPLETED","sponsor":"Chungbuk National University Hospital","startDate":"2016-01-01","conditions":"Type2 Diabetes","enrollment":600},{"nctId":"NCT05266404","phase":"PHASE1","title":"Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-21","conditions":"Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)","enrollment":46},{"nctId":"NCT05429554","phase":"","title":"The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"MTI University","startDate":"2022-06","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT02041234","phase":"PHASE4","title":"Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment","status":"COMPLETED","sponsor":"Khoo Teck Puat Hospital","startDate":"2014-02","conditions":"Type II Diabetes in Subjects BMI 27 to 32","enrollment":40},{"nctId":"NCT05162690","phase":"PHASE2, PHASE3","title":"Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-05-01","conditions":"Diabetic Peripheral Neuropathy","enrollment":40},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT03486964","phase":"","title":"Use of Incretins in Diabetic Patients","status":"COMPLETED","sponsor":"University of Pavia","startDate":"2018-03-27","conditions":"Diabetes Mellitus, Type 2","enrollment":2234},{"nctId":"NCT05386186","phase":"PHASE4","title":"The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes","enrollment":192},{"nctId":"NCT05359341","phase":"NA","title":"Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2020-09-20","conditions":"Diabete Type 2","enrollment":175},{"nctId":"NCT05353673","phase":"PHASE2","title":"The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2021-06-01","conditions":"Immune Thrombocytopenia, Blood Coagulation Disorders, Thrombocytopenia","enrollment":120},{"nctId":"NCT05290506","phase":"PHASE3","title":"Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2020-08-01","conditions":"PreDiabetes, Type 2 Diabetes","enrollment":50},{"nctId":"NCT04976283","phase":"PHASE4","title":"Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver","status":"UNKNOWN","sponsor":"Getz Pharma","startDate":"2021-09-15","conditions":"Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD","enrollment":123},{"nctId":"NCT02130687","phase":"NA","title":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":106},{"nctId":"NCT04283318","phase":"NA","title":"Prolonged Fasting on Glucose Metabolism and Hormonal Regulation in Healthy, Obese and Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2018-06-13","conditions":"Healthy, Obesity, Type 2 Diabetes Mellitus","enrollment":80}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"DRUG INEFFECTIVE"},{"count":3,"reaction":"NAUSEA"},{"count":3,"reaction":"VOMITING"},{"count":2,"reaction":"ABDOMINAL PAIN"},{"count":2,"reaction":"WEIGHT DECREASED"},{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"ADULT T-CELL LYMPHOMA/LEUKAEMIA"},{"count":1,"reaction":"ANURIA"},{"count":1,"reaction":"BLOOD GLUCOSE DECREASED"},{"count":1,"reaction":"BLOOD SODIUM DECREASED"}],"_approvalHistory":[],"publicationCount":473,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sitagliptin","Januvia","Janumet","Ristaben","Tesavel"],"phase":"marketed","status":"active","brandName":"DPP4 inhibitor","genericName":"DPP4 inhibitor","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DPP4 inhibitors block the enzyme dipeptidyl peptidase-4, which prolongs the activity of incretin hormones that stimulate insulin secretion in response to glucose. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}